The Genitourinary (GU) Cancer Program is a multi-disciplinary program focused on the pathogenesis, diagnosis, prevention and treatment of genitourinary malignancies. While the emphasis on this Program has been and will continue to be on bladder and prostate cancers (the most common genitourinary malignancies), we are developing increasing emphasis in renal and testicular cancer as well. The scientific goal of the molecular aspects of genitourinary cancer progression and to translate discoveries into novel diagnostic and therapeutic strategies; (c) to examine the epidemiology of genitourinary cancer in order to develop hypotheses regarding possible causation, molecular etiology, and novel prevention strategies; and (d) to develop and test new surgical, chemotherapeutic, radiotherapeutic, biologic and combined modality approaches to the treatment of genitourinary cancer. These goals are being addressed through our considerable strengths in epidemiology, basic research, translational research, and clinical investigation. The GU Program which was newly proposed in the previous grant cycle, now contains 26 members from eight departments. The Program is supported by 29 peer-reviewed research projects (up from eight peer- reviewed research grants in the previous application) from 14 principal investigators. Funding totals are now over $4.7 million in direct costs annually, and a large proportion of the funded grants are multi- disciplinary. The GI Program is directly supported by the Cancer Center Core Facilities, including major involvement with Biostatistics and Cancer Research Informatics Core Facilities. The Cancer Center also fosters interaction in the GU Program through sponsorship of monthly meetings of the GU Group, GU focused Cancer Center Grand Rounds, and GU Retreats. Thus, the GU Program is an integral and well-integrated part of the USC/Norris Comprehensive Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Lee, Brian H; Stallcup, Michael R (2018) Different chromatin and DNA sequence characteristics define glucocorticoid receptor binding sites that are blocked or not blocked by coregulator Hic-5. PLoS One 13:e0196965
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Woodham, Andrew W; Cheloha, Ross W; Ling, Jingjing et al. (2018) Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses. Cancer Immunol Res 6:870-880
Matsusaka, S; Wu, A H; Cao, S et al. (2018) Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J 18:262-269
Veyseh, Maedah; Ricker, Charite; Espenschied, Carin et al. (2018) Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. Front Oncol 8:259
Vannini, Ivan; Fanini, Francesca; Fabbri, Muller (2018) Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 48:128-133
Sunakawa, Yu; Yang, Dongyun; Cao, Shu et al. (2018) Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer. Clin Colorectal Cancer 17:e741-e749
Bluthenthal, Ricky N; Chu, Daniel; Wenger, Lynn D et al. (2018) Differences in time to injection onset by drug in California: Implications for the emerging heroin epidemic. Drug Alcohol Depend 185:253-259
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Skeate, Joseph G; Da Silva, Diane M; Chavez-Juan, Elena et al. (2018) Nano-Pulse Stimulation induces immunogenic cell death in human papillomavirus-transformed tumors and initiates an adaptive immune response. PLoS One 13:e0191311

Showing the most recent 10 out of 842 publications